Kevin C. Zorn, MD, FRCSC, FACS presented “Overview of Current MIST: Practical Considerations ” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
How to cite: Zorn, Kevin C. “Overview of Current MIST: Practical Considerations ” November, 2023. Accessed Nov 2024. https://grandroundsinurology.com/overview-of-current-mist-practical-considerations/
Overview of Current MIST: Practical Considerations – Summary
Kevin C. Zorn, MD, FRCSC, FACS, provides an authoritative overview of current minimally invasive surgical techniques (MIST) for the treatment of benign prostatic hyperplasia (BPH). His analysis emphasizes the advancements in MIST and their role in providing effective and patient-friendly alternatives to traditional surgical approaches.
Dr. Zorn highlights the primary MIST options currently available, including transurethral resection of the prostate (TURP), photoselective vaporization of the prostate (PVP), holmium laser enucleation of the prostate (HoLEP), and newer techniques such as water vapor thermal therapy and prostatic urethral lift (PUL). The procedural nuances of each MIST option are discussed in detail.
Dr. Zorn examines the outcomes and benefits of MIST as well as the challenges and limitations of the procedures. Future directions in MIST are considered, with Dr. Zorn highlighting ongoing research and innovation to further refine these techniques and expand their applicability. The integration of advanced imaging technologies and the development of novel therapeutic devices hold promise for enhancing the precision and effectiveness of MIST.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Kevin C. Zorn, MD, FACS, FRCSC, is the founder of the BPH Canada Prostate Institute, a personalized, private, prostate solution center founded in 2023 to offer all approved BPH therapies to Canadian men, and director of Robotic & MIS BPH Prostate Surgery, Mont-Royal Surgical Center. Dr. Zorn is a former associate professor of urology at the University of Montreal (CHUM) and the University of Chicago, sub-specializing in robotic surgery and benign prostatic hyperplasia (BPH) surgical care.
Dr. Zorn attended McGill University for his pre-med program, his medical degree, and his residency in urological surgery. He became a fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC) in 2005. Dr. Zorn also completed a two-year fellowship in oncology and endourology at the University of Chicago. In 2007, he became American Board of Urology certified in urology and a fellow of the American College of Surgeons.
Research and innovation have been the hallmarks of Dr. Zorn’s career. Among his many firsts, he was the first in Canada and Québec to use many new BPH technologies, including Greenlight XPS, Rezum, iTind, Optilume, Aquablation and Zenflow. He has also been the first in Canada to introduce cutting-edge technologies including the Clarius and ButterflyIQ point-of care ultrasound (POCUS), as well as disposable AMBU4 cystoscopes for faster patient care and greater safety. He is among the first physicians globally to be named as a Center of Excellence for Rezum and Greenlight vaporization and VIT (vapor incision technique). He is an international speaker and surgical trainer for these techniques.
Dr. Zorn is the senior author of the Male lower urinary tract symptoms (LUTS)/BPH guidelines for the 2018 and 2022 Canadian Urological Association (CUA) and consulted on the American Urological Association BPH guidelines. He has also helped create national online programs in robotic prostate cancer care and rehabilitation as well as the CUA BPH patient decision-aid tool. Dr. Zorn has authored 400 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care. With such accolades, Dr. Zorn has become a sought-afterspeaker, teacher and researcher. He has traveled to lecture, teach, and proctor surgery around the world, and is intimately involved with the development of several pioneering BPH technologies. In 2024, Dr. Zorn retired from his position at the University of Montreal to dedicate his full clinical practice to BPH Canada.
